Nuclear Medicine

ITM receives Complete Response Letter for ITM-11

By AuntMinnie.com staff writers

The FDA stated that it's unable to approve the NDA in its present form.

August 10, 2026

Plus Therapeutics rebrands as Cerenome

By AuntMinnie.com staff writers

The move reflects the company's evolution from a therapeutics-focused organization into an integrated central nervous system (CNS) oncology company.

August 3, 2026

Novartis secures expanded approval for Pluvicto

By AuntMinnie.com staff writers

Pluvicto can now be used as therapy in patients with PSMA-positive metastatic hormone-sensitive prostate cancer, in combination with an androgen receptor pathway inhibitor.

July 31, 2026

SNMMI issues analysis of 2027 HOPPS proposed rule

By AuntMinnie.com staff writers

The proposed rule includes several positive code-level changes for nuclear medicine providers.

July 29, 2026

ITM launches new oncology therapeutics division

By AuntMinnie.com staff writers

Lumara Bio will focus resources toward commercial readiness for ITM's lead drug candidate, lutetium-177 (Lu-177) edotreotide (ITM-11).

July 27, 2026

Lutetium-177 PSMA-617 shows promise in earlier-stage prostate cancer

By Will Morton

Across 14 studies, PSA50 response rates (the number of patients with at least a 50% drop in PSA) ranged from 44% to 100%.

July 21, 2026

GE HealthCare introduces MIM Anyware remote access platform

By AuntMinnie.com staff writers

The platform allows authorized users to access MIM software applications from any location without local installation.

July 21, 2026

AdvanCell raises $315M for targeted alpha therapy

By AuntMinnie.com staff writers

The company is developing ADVC001, a lead-212 (Pb-212)-based targeted alpha therapy for metastatic prostate cancer.

July 15, 2026

Nucs AI, Segmed to build AI validation platform for theranostics

By AuntMinnie.com staff writers

The companies will develop disease-specific registries, curated research cohorts, and validation frameworks.

July 14, 2026

Actineer completes Ra-226 recycling process to support Ac-225 supply

By AuntMinnie.com staff writers

This process aims to improve Ac-225 supply predictability and cost stability, as well as reduce waste generation.

July 14, 2026

Molecular Partners, Orano Med dose first patients in MP0712 trial

By AuntMinnie.com staff writers

MP0712 is a designed ankyrin repeat protein (DARPin) that targets delta-like ligand 3 (DLL3).

July 2, 2026

RefleXion Medical submits FDA 510(k) for Anchor Point tumor tracking

By AuntMinnie.com staff writers

RefleXion Medical is seeking FDA clearance for the company's Anchor Point Tracking tech for radiotherapy use.

June 30, 2026

Page 1 of 444

Next Page